BDSX Biodesix Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BDSX

Price (delayed)

$1.4

Market cap

$135.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$170.13M

Biodesix, Inc. operates as a biotechnology company. The Company offers non-small cell lung cancer pretreatment serum tests and laboratory testing. Biodesix provides diagnostic tools and equipment for blood and tissue ...

Highlights
BDSX's EPS has soared by 59% year-on-year and by 27% since the previous quarter
The company's gross profit rose by 50% YoY and by 16% QoQ
Biodesix's quick ratio has plunged by 52% YoY but it has increased by 31% from the previous quarter
BDSX's debt has soared by 91% YoY and by 20% QoQ
The equity has dropped by 78% year-on-year
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.biodesix.com
Peers: OPGN NEO

Key stats

What are the main financial stats of BDSX
Market
Shares outstanding
96.94M
Market cap
$135.72M
Enterprise value
$170.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
27.66
Price to sales (P/S)
2.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.47
Earnings
Revenue
$49.09M
EBIT
-$42.61M
EBITDA
-$37.1M
Free cash flow
-$45.93M
Per share
EPS
-$0.64
Free cash flow per share
-$0.56
Book value per share
$0.05
Revenue per share
$0.6
TBVPS
$0.93
Balance sheet
Total assets
$99.1M
Total liabilities
$94.52M
Debt
$60.69M
Equity
$4.58M
Working capital
$6.27M
Liquidity
Debt to equity
13.25
Current ratio
1.19
Quick ratio
1.02
Net debt/EBITDA
-0.93
Margins
EBITDA margin
-75.6%
Gross margin
73.5%
Net margin
-106.2%
Operating margin
-84.2%
Efficiency
Return on assets
-60.6%
Return on equity
-30,185.8%
Return on invested capital
-71%
Return on capital employed
-64.9%
Return on sales
-86.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BDSX stock price

How has the Biodesix stock price performed over time
Intraday
6.87%
1 week
12.9%
1 month
-9.68%
1 year
-15.15%
YTD
-23.91%
QTD
-2.1%

Financial performance

How have Biodesix's revenue and profit performed over time
Revenue
$49.09M
Gross profit
$36.08M
Operating income
-$41.34M
Net income
-$52.15M
Gross margin
73.5%
Net margin
-106.2%
The company's gross profit rose by 50% YoY and by 16% QoQ
BDSX's net margin is up by 38% YoY and by 26% QoQ
The operating margin has increased by 36% year-on-year and by 23% since the previous quarter
Biodesix's revenue has increased by 28% YoY and by 11% QoQ

Growth

What is Biodesix's growth rate over time

Valuation

What is Biodesix stock price valuation
P/E
N/A
P/B
27.66
P/S
2.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.47
BDSX's EPS has soared by 59% year-on-year and by 27% since the previous quarter
The equity has dropped by 78% year-on-year
Biodesix's revenue has increased by 28% YoY and by 11% QoQ
The price to sales (P/S) is 22% lower than the last 4 quarters average of 3.0

Efficiency

How efficient is Biodesix business performance
BDSX's ROIC has soared by 81% YoY and by 35% QoQ
BDSX's ROS is up by 42% year-on-year and by 29% since the previous quarter
BDSX's return on assets is up by 32% year-on-year and by 19% since the previous quarter

Dividends

What is BDSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BDSX.

Financial health

How did Biodesix financials performed over time
The company's total assets is 4.8% higher than its total liabilities
Biodesix's quick ratio has plunged by 52% YoY but it has increased by 31% from the previous quarter
The company's current ratio fell by 49% YoY but it rose by 35% QoQ
The debt to equity has soared by 138% since the previous quarter
BDSX's debt has soared by 91% YoY and by 20% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.